Please ensure Javascript is enabled for purposes of website accessibility
Главная > Продукты > Антитела > Биосимиляры

Anti-Human IL-17A/F Heterodimer Reference Antibody (Bimekizumab, RUO) (HS856036)

Anti-Human IL-17A/F Heterodimer Reference Antibody (Bimekizumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Bimekizumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Bimekizumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Bimekizumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Bimekizumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Bimekizumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Bimekizumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Bimekizumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Bimekizumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Bimekizumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Bimekizumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Bimekizumab, RUO)
Цена(USD):
Спецификация:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
Количество:
Свяжитесь с нами
  • Обзор

  • Изображения

  • Ссылки

  • Даташит

  • SDS

Обзор
Каталожный номерHS856036
Описание
Research Grade Bimekizumab (HS856036) is a humanized monoclonal antibody detecting CTLA-8 in ELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable for Human.
Highlights
  • ●Multi-Application — Validated across multiple applications.
Реактивность видовHuman
ПримененияELISA, Bioactivity: FCM, Functional assay, Research in vivo
Хозяинский видHuman
КлоональностьMonoclonal
ИзотипIgG1-kappa
Проверенные приложения WB, FCM
Цель CTLA-8, CTLA8, Cytotoxic T-lymphocyte-associated antigen 8, IL-17, IL-17A, IL17, IL17A, Interleukin-17A, Cytokine ML-1, IL-17F, IL17F, Interleukin-17F
Уровень эндотоксинов < 10 EU/mg
Чистота >95% as determined by SDS-PAGE.
Очистка Protein A/G purified from cell culture supernatant.
Номер доступа Q16552, Q96PD4
Форма Liquid
Буфер хранения 0.01M PBS pH 7.4.

Пожалуйста, обратитесь к конкретной информации о буфере в печатной версии даташита или в индивидуальном сертификате качества (COA) для партии.

Устойчивость и хранение Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Альтернативные названияCDP4940, UCB-4940, UCB4940, 1418205-77-2
ФонAfasevikumab, also known as RG7624, is a human antibody inhibitor for human interleukin 17A (IL17A) and interleukin 17F (IL17F). This drug was developed by Genentech and has been investigated in the study of the treatment of inflammation diseases like autoimmune disorders. In 2013, Genentech completed a phase Ib study for the treatment of autoimmune disorders in Canada. However, it had been discontinued in 2015. In 2016, researchers used afasevikumab to conduct a phase I clinical trials for the treatment of inflammation in USA with no specified.
• IL-17 and IL-17-producing cells in protection versus pathology., PMID:35790881
• The IL-17 Family of Cytokines in Health and Disease., PMID:30995505
• The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond., PMID:30127781
• Functional specialization of interleukin-17 family members., PMID:21349428
• Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease., PMID:31866067
• The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases., PMID:37600764
• The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis., PMID:30109481
• Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies., PMID:37373452
• Rhythmic IL-17 production by γδ T cells maintains adipose de novo lipogenesis., PMID:39478228
• Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation., PMID:29275332
Примечание For research use only. Not suitable for clinical or therapeutic use.
Isotype Control Human IgG1 Recombinant Isotype Control Antibody (HyHEL-10) (HV080407)
Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)
Изображения
  • Anti-Human IL-17A/F Heterodimer Reference Antibody (Bimekizumab, RUO)

    Bioactivity

    Detects IL17F in indirect ELISAs.

  • Anti-Human IL-17A/F Heterodimer Reference Antibody (Bimekizumab, RUO)

    SEC-HPLC

    SEC-HPLC detection for Research Grade Bimekizumab.

  • Anti-Human IL-17A/F Heterodimer Reference Antibody (Bimekizumab, RUO)

    Bioactivity

    Detects Human IL17A in indirect ELISAs.

  • Anti-Human IL-17A/F Heterodimer Reference Antibody (Bimekizumab, RUO)

    Flow Cytometry

    Flow-cytometry using anti-human IL17A&IL17F antibody. Jurkat cells were fixed and permeabilized, then stained with an irrelevant antibody (Blue Histogram) or an anti-human IL17A&IL17F monoclonal antibody (Catalog HS856036, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer.

  • Anti-Human IL-17A/F Heterodimer Reference Antibody (Bimekizumab, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade Bimekizumab

  • Anti-Human IL-17A/F Heterodimer Reference Antibody (Bimekizumab, RUO)

    Western blot

    Western blot analysis was performed using anti-IL17A monoclonal antibody at 1μg/ml on various samples.
    Lane 1: recombinant human IL17A (Catalog No: HS856011), 50ng
    Lane 2: recombinant human IL17A (Catalog No: HS856011), 30ng
    Lane 3: recombinant human IL17A (Catalog No: HS856011), 20ng
    Lane 4: recombinant human IL17A (Catalog No: HS856011), 10ng

Ссылки
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Рекомендация

Свяжитесь с нами для индивидуальных предложений, оптовых запросов и других вопросов.

Почта: [email protected]

Список дистрибьюторов